@article {VOS2511, author = {MAAIKE J. VOS and TJEERD J. POSTMA and FRANS MARTENS and BERNARD M.J. UITDEHAAG and MARINES A. BLANKENSTEIN and W. PETER VANDERTOP and BEN J. SLOTMAN and JAN J. HEIMANS}, title = {Serum Levels of S-100B Protein and Neuron-specific Enolase in Glioma Patients: A Pilot Study}, volume = {24}, number = {4}, pages = {2511--2514}, year = {2004}, publisher = {International Institute of Anticancer Research}, abstract = {Background: Serum levels of S-100B protein (S-100B) and neuron-specific enolase (NSE) are elevated after various cerebral injuries and are considered markers of central nervous system damage. In brain tumor patients, literature data on the prognostic value of serum S-100(B) and NSE levels are scarse and conflicting. Patients and Methods: We assessed serum S-100B and NSE levels in 20 consecutive cerebral glioma patients, and evaluated serum levels in relation to survival to determine their prognostic value. Kaplan-Meier survival curves were constructed for patients with {\textquotedblleft}high{\textquotedblright} (\> median value) versus {\textquotedblleft}low{\textquotedblright} (<= median value) serum S-100B and NSE levels. Results: A statistically significant shorter survival was found in patients with high serum S-100B levels, whereas a similar classification of patients based on serum NSE levels demonstrated no statistically significant difference in survival between the two groups. Conclusion: These preliminary data suggest that serum S-100B might be a prognostic variable in cerebral glioma patients. Further study is warranted to evaluate whether serum S-100B is an additional, independent prognostic variable. Copyright{\textcopyright} 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/24/4/2511}, eprint = {https://ar.iiarjournals.org/content/24/4/2511.full.pdf}, journal = {Anticancer Research} }